Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV-E6-Specific TCR-T Cells in HPV-Positive Head and Neck or Cervical Cancer
NCT03578406Phase 1Completed
- Sponsor
- Xinqiao Hospital
- Start
- Sep 2018
- Primary completion
- Apr 2022
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of E6 T cell receptor in Cervical Cancer (CC) and head and neck squamous cell carcinoma (HNSCC), sponsored by Xinqiao Hospital. Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Sep 2018; status: completed.
02
Drugs
E6 T cell receptor
03
Conditions
Cervical Cancer (CC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03578406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578406.